Asset Details
Do you wish to reserve the book?
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Do you wish to request the book?
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
2020
Overview
This phase 3 trial evaluated the safety and efficacy of inclisiran, a small interfering RNA that inhibits hepatic PCSK9 synthesis, in 482 adults with heterozygous familial hypercholesterolemia, who received subcutaneous injections of inclisiran or placebo on days 1, 90, 270, and 450. Changes in cholesterol were assessed up to day 540.
We currently cannot retrieve any items related to this title. Kindly check back at a later time.